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The chemical mediators of immediate-type hy-
persensitivity reactions can be detected in or 
obtained from a variety of tissues, including the 
skin, in which a principle cell of origin is the mast 
cell. In this report we will review the cellular origin 
of the chemical mediators, the biochemical charac-
teristics of their generation and release , and the 
current knowledge of their structure and function. 
The consequences of uncontrolled mast cell activa-
tion include both an acute pharmacologic phase re-
lated to the release of factors that increase vascular 
permeability and constrict smooth muscle, and a 
subacute inflammatory phase related to the spe-
cific recruitment by mediators of polymorphonu-
clear leukocytes and the activation of platelets. In-
asmuch as the mast cell resides in tissues rather 
than in the circulation, it is tempting to speculate 
that its physiologic role in response to specific im-
munologic activation is to achieve the recruitment 
of proteins and cells from the blood without exten-
sive local tissue injury. In addition, uncontrolled 
mast cell activation could proceed to a self-perpet-
uating inflammatory state . 
CHEMICAL MEDIATORS OF IMMEDIATE-TYPE 
HYPERSENSITIVITY REACTIO NS (TABLE Il 
Human lung obtained from allergic individuals 
releases histamine [1], slow reacting substance of 
anaphylaxis (SRS -A) [2), and eosinophil chemo-
tactic factor of anaphylaxis (ECF -A) [3) upon 
challenge with specific allergen; and the same 
mediators [3,4], as well as platelet-activating fac -
tor (PAF) [5), are obtained from normal respira-
tory tissue passively sensitized with IgE antibody 
and challenged with specific antigen. Antigen-
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Abbreviations: 
cAMP: 3' ,5'-cyclic adenosine monophosphate 
ECF-A: eosinophil chemotactic fador of anaphylaxis 
NCF: neutral chemotactic factor 
NIF: neutrophif inhibitory factor 
PAF: platelet-activating factor 
SRS-A: slow reacting substance of anaphylaxis 
TAMe: tosyl-L-arginine methyl ester 
induced histamine release after passive sensitiza-
tion with IgE-rich serum has also been demon-
strated from human skin slices [6). In addition, 
histamine, ECF -A, and SRS-A were obtained from 
guinea-pig skin fragments after passive sensitiza-
tion with IgG 1 and challenge with specific antigen 
[7 ). 
Antigen-induced histamine release in human 
skin slices reached a plateau at 29°C [6), whereas 
the release of histamine, ECF-A and SRS-A from 
guinea:.pig lung fragments was reduced at 32°C 
and strikingly impaired at 27°C as compared to 
37°C [8). The responsiveness at temperatures 
below 37°C in skin is noteworthy in view of the fact 
that peripheral skin temperatures are variable and 
remain uniform only over distances of millimeters 
[9 J. The IgE-mediated release of histamine from 
human skin slices was suppressed by epinephrine 
[10) at concentrations slightly higher than those 
required to achieve comparable inhibition of IgE-
dependent mediator release in human lung [4) or 
monkey lung [11). The effect of epinephrine was 
blocked by propranolol, a ,a-adrenergic blocking 
agent, indicating that epinephrine interacted with 
specific (3 receptors in expressing it s inhibitory 
function. Theophylline , an inhibitor of cytoplas-
mic phosphodiesterases , at a concentration that 
did not produce inhibition by itself, augmented the 
effect achieved by epinephrine; this finding is 
attributed to the synergism resulting from the 
activation of adenyl ate cyclase to form 3' ,5' -cyclic 
adenosine monophosphate (cAMP) from ATP and 
suppression of cAMP catabolism to 5'-AMP. This 
circumstantial evidence indicating that increases 
in levels of cyclic AMP inhibit IgE-mediated 
histamine release was supported by the finding 
that dibutyryl cyclic AMP also was inhibitory in a 
dose -response fashion. 
Disodium cromoglycate, an agent that inhibits 
histamine release from cutaneous mast cells of 
rodents [12) as assessed by the passive cutaneous 
anaphylaxis reaction, also suppresses IgE-mediated 
histamine release from human lung [13,14). In 
contrast, it fails to suppress the Prausnitz-
Kiistner reaction [14) and the IgE-mediated hista-
mine release from human basophils [15] and 
from human skin slices [16 J. In this regard, it 
should be noted that disodium cromoglycate has a 
tachyphylactic effect on human lung fragments 
[17 J and rodent · skin [18 J such that the inhibitory 
effect disappears at higher drug doses. It is of 
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interest that the fungal metabolite, cytochalasin 
B, reversibly inhibits the IgE-dependent release of 
histamine from skin slices in a dose-related fashion 
[19]. In contrast , in human lung fragments , the 
immunologic release of histamine is enhanced by 
cytochalasin A and cytochalasin B , whereas the 
concomitant formation of SRS-A is inhibited [20]. 
Histamine ((3-imidazoly lethy lamine) 
Mast cells which are located predominately in 
the perivenular areas of the connective tissue 
cont ain histamine in association with the granules. 
Regardless of whether histamine is contained in 
mast cells , in circulating elements such as baso-
phils or platelets, or in the parietal region of the 
stomach, it is formed from L-histidine and de-
graded by either oxidative deamination or by 
methylation and oxidative deamination [21] . His-
tamine receptors have recently been classified as 
Hl and H2 [22] based on their respective inhibition 
by dist inct groups of antihistamines. For example, 
the positive ionotropic and chronotropic cardiac 
regulation [23 ], the gastric secretory regulation, 
(24) and the suppression of the effector functions of 
T -lymphocytes [25] and human basophil leuko-
cytes [26] occur via an H2 receptor linked to 
adenylate cyclase . Such pathobiologic effects as 
the production of leaking venules , attributed to 
partial disconnection of the endothelium [27] and 
smooth muscle contraction by direct and cholin-
ergic reflex mechanisms [28 ,29], appear to be 
mediated by the Hl receptor. 
Eosinophil Chemotactic Factor of Anaphylaxis 
(ECF-A) 
ECF -A is a preformed mediator discovered in 
1971 [3,30] that has been specifically associated 
with the rat mast cell [31) and the human leukemic 
basophil [32]. ECF -A extracted or released 
immunologically from human or guinea-pig lung 
fragments, rat mast cells, and human leukemic 
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by gel filtration on Sephadex G-25 [31 ,32] and is 
susceptible to inactivation by digestion with sub-
tilisin or pronase. High-voltage electrophoresis on 
paper at neutral pH after gel filtration resolved 
human lung ECF-A into two discrete peaks of 
anodally migrating eosinophil chemotactic activ-
ity , indicating that at least two acidic peptides 
have the function al at tributes of ECF -A [33 ]. More 
recently, these activities have been identified as 
residing in two tetrapeptides with differing N-ter-
minal amino acids [34]. The synthetic tetrapep-
tides are identical to the natural mediators with 
respect to function and concentration required to 
achieve those functions. The responses in vitro 
include the preferential directed migration of eo-
sinophils [33 ], the deactivation of eosinophils for 
subsequent migra t ion in response to a further eo-
sinophilotactic stimulus and stimulation of the 
hexose monophosphate shunt [35]. It seems likely 
that the specific attraction of eosinophils followed 
by their deactivation upon arrival would permit the 
cell to exert a regulatory function. Examples of 
such a function include the specific inact ivation of 
SRS-A through the eosinophil's content of arylsul-
fa tase B [36] and the antibody-mediated destruc-
tion of schistosomula [37]. 
Slow Reacting Substance of Anaphylaxis (SRS -A) 
SRS-A is an acidic, sulfur-containing [38] chem-
ical mediator of approximately 500 molecular 
weight [39] that is inactivated by arylsulfatase 
B of human eosinophil [36] or lung [40]. In con-
trast to the preformed mediators, histamine and 
ECF-A, SRS-A appears in tissues or cells only 
after immunologic activation and immediately 
before its release [41,42). The mast cell has been 
presumed to be the cell source, owing to the 
generation of SRS-A following IgE-dependent 
reactions in human lung [4] and nasal polyp [43] 
fragments and in human lung [41] and peripheral 
leukocyte [44] cell suspensions. SRS-A generation 
continues when the cellular content has reached a 
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plateau and the release of preformed mediators is 
complete [41], suggesting involvement of an addi-
tional cell type or generation by the mast cell at 
sites not linked to the release of preformed media-
tors. That more than one celi type and more than 
one immunoglobulin class can participate in 
SRS-A generation is illustrated in the rat by the 
release of SRS-A into the peritoneal cavity by 
either an IgE-mast cell-dependent [45] or an IgGa-
complement-neutrophil-dependent [46] mecha-
nism. It may well be that unstored mediators will 
be derived from multiple cell types if their genera-
tion is linked in some manner to the events of 
exocytosis. SRS-A increases vascular permeabil-
ity upon intracutaneous injection [47] into rats, 
guinea pigs, and monkeys and contracts smooth 
muscle independent of a cholinergic mechanism 
[29 ]. 
Other Potential Mediators 
P AF, assessed by its ability to release histamine 
or radiolabeled serotonin from rabbit and human 
platelets, has been released from rabbit [48,49] and 
human [50] cell suspensions and from human lung 
fragments [5] by IgE-dependent mechanisms. 
That the source of this chemical mediator in 
peripheral blood is basophils was first recognized 
by Siraganian and Osler [49] and is supported by 
the release of a platelet-activating principle from 
suspensions of leukemic human basophils upon 
interaction with the calcium ionophore [32]. 
Whether these activities represent a single factor 
remains to be determined, but it seems unlikely in 
view of observed differences with respect to size 
and enzyme susceptibility [50,51] of material gen-
erated with rabbit leukocytes [50] as compared to 
the rat peritoneal cavity [51]. 
Antigen challenge of IgE-sensitized human lung 
fragmen ts [52] and peripheral leukocytes [53 ] 
releases activities capable of hydrolyzing tosyl-L-
arginine methyl ester (TAMe). Human leukoycte 
suspensions also release an activity that cleaves 
bradykinin from kininogen, but the identity of this 
principle with the esterase is not yet established. 
A second factor, predominantly a neutrophil 
chemotactic factor (NCF), was recognized in ex-
tracts of human leukemic basophils [32] and of hu-
man lung fragments [31] and in the venous efflu-
ent of the cold-challenged extremity of patients 
with cold urticaria [54]. This activity was sepa-
rated from ECF-A by filtration on Sephadex G-25 
The release of this as yet uncharacterized media-
LOr might account for the accumulation of neutro-
phils at the site of an allergic reaction which, 
through the release of lysosomal enzymes, would 
199ravate the tissue injury process. It should also 
')e noted that ECF-A will attract neutrophils when 
,;he eosinophil content of the responding cell pool 
:s 10% or less [55]. 
Chemical mediators such as the prostaglandins 
:hat are readily formed as altered membranes 
make available potential substrate [56] are consid-
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ered secondary rather than primary mediators of 
the acute allergic reaction. The same is true of 
bradykinin that is derived by a sequential plasma 
protein sequence after activation of Hageman 
factor [57] by altered basement membrane, or 
collagen [58]. The intermediates and end products 
of prostaglandin biosynthesis observed upon anti-
gen challenge of sensitiz~d guinea-pig lung do not 
appear in the presence of eicosatetraynoic acid 
[59,60], whereas primary mediator release is unaf-
fected. Conversely, the suppression of primary 
mediator release in this system by the introduction 
of disodium cromoglycate has no effect on the 
appearance of prostaglandin intermediates or end 
products. The latter suggests that the prosta-
glandins are derived not only by the action of 
primary chemical mediators upon target tissue, 
but as a result of the processing of immune 
com plexes by lung macrophages. These secondary 
mediators may well be of great significance not 
only because of the ease with which they are 
elaborated and their direct tissue effects, but also 
because of their capacity to alter primary mediator 
release and action through an effect on cyclic 
nucleotide levels [61,62]. For example, the com-
bination of prostaglandins and histamine elicits 
pruritus [63] out of proportion to that anticipated 
for histamine in view of the failure of prostagland-
ins alone to elicit itching. 
THE MAST CELL 
Although the origin of mast cells is in dispute, 
the most common view is that fixed, undifferen-
tiated, mesenchymal cells are the chief source [64]. 
Mast cells are found in organs rich in connective 
tissue, such as mammary gland, lung parenchyma, 
the respiratory and digestive tracts, skin, and 
serous membranes in general. Normal human skin 
contains between 5,120 and 9,472 mast cells per 
mm 3 with a mean of 7,225 [65]. 
Mast cells vary with respect to size and shape 
and are influenced by surrounding tissue; in loose 
connective tissue, they assume round shapes, 
whereas in fibrous tissue of the skin and organ 
capsules, they may appear as elongated elements. 
Mast cells contain prominent nuclei that are round 
or oval in shape with well-defined nucleoli. The 
cytoplasm contains spheroidal basophilic granules 
that may be so numerous that they partially or 
completely obscure other cytoplasmic structures. 
Ultrastructural studies [64,66] have been per-
formed mainly on mast cells obtained from the 
peritoneal cavities of rats, mice, or hamsters which 
represent the only known sources of free cells. 
The mast cells contain mitochondria that are 
surrounded by a double membrane with transverse 
internal lamellae; however, these organelles are not 
numerous. The rough endoplasmic reticulum is 
compressed into the intergranular cytoplasmic 
spaces and cytoplasmic microtubules are present. 
The Golgi apparatus appears as a series of parallel 
membranes that are associated with vesicles. It has 
been postulated [67] that granule synthesis occurs 
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in the progranules of the Golgi zone inside a 
membrane; finely granular material from the 
rough endoplasmic reticulum is added to the 
vacuoles containing aggregates of progranules. The 
latter fuse with continued accumulation of mate-
rial and subsequent reorganization to form the 
complete granule. An alternative hypothesis is that 
the granules develop in the cytoplasm independent 
of the Golgi apparatus [68]. 
The mast cell granules are bounded by a mem-
brane and their internal structure shows considera-
ble variation in different species. A variability in 
granule structure is observed in human mast cells. 
Two subgranular components are common to all 
human mast cell granules: dense lamellar struc-
tures and fine granular material [69,70]. In addi-
tion, human skin mast cells have the distinguish-
ing features of long villous extensions of the plasma 
membrane, granules that contain crystalline lat-
tices and lJrominent microfilaments [71]. 
The ultrastructural characteristics of the de-
granulation of cells have been studied in human 
skin of patients with urticaria pigmentosa and 
normal individuals after stroking or injection with 
compound 48/80 [72-75]. Four types of degranula-
tion [75] were noted: the separation of protruded 
areas on the cell surface such that the released 
granule was enclosed by a portion of the plasma 
membrane; perigranular vacuole formation fol-
lowed by granule expulsion; cell lysis; and the loss 
of the electron-dense nature of the granules with 
their retention within the cytoplasm to produce a 
honeycomb appearance. 
The mast cell granules contain sulfated acidic 
glycosaminoglycans that are responsible for their 
metachromasia. At least 70 to 90 % of these sub-
stances are heparin [76-78]. Isolated rat mast cell 
granules contain proteolytic enzymes in an active 
form, including a chymase that has an alkaline pH 
optimum [79] and enzymes with acidic pH optima. 
These acid hydrolases that include acid phospha-
tase, /3 glucuronidase, and N-acetyl-/3-g1ucosamin-
idase [80] may extend to the mast cell the ca-
pacity to degrade polysaccharide constitutents 
of connective tissue. Collagenolytic activity has 
also recently been recognized [81]. 
ASSESSMENT OF MAST CELL PARTICIPATIO N IN 
VARIOUS FORMS OF CUTANEOUS INFLAMMATIO N 
The activation of human skin mast cells by 
IgE-dependent mechanisms is well recognized, 
based upon both the Prausnitz-Kiistner phenome-
non in vivo [82,83] and the release of chemical 
mediators in vitro [6]. Mast cells may also be 
activated secondary to the formation of immune 
complexes with concomitant activation of the 
classic complement system and the subsequent 
elaboration of the anaphylatoxins C3a and C5a 
[84]. C3a in amounts of 2.1 x 10- 1 2" moles and C5a 
at 1 x ' 10- 15 moles [84] injected directly into 
human skin result in erythema, urticaria, and 
pruritus that has been abolished in the case of C3a 
by pretreatment with antihistamines [84,85]. Ul-
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trastructural studies show mast cell degranulation 
[85] with gaps between the endothelial cell junc-
tions of venules, discontinuities of the basement 
membrane and the absence of infiltrating leuko-
cytes with low doses of C3a [85] and perivenular 
neutrophils at higher doses [86]. More recently, 
mast cell hypogranulation has been noted in stud-
ies of delayed type hypersensitivity in human skin 
elicited by a tuberculin reaction or dinitro-
chlorobenzene; hypo granulation was more promi-
nent in the papillary and superficial reticular 
dermis [87]. There was edema of the papillary 
dermis with compaction of the venules that showed 
gaps between the endothelial cells. In studies of the 
IgE-dependent reaction, there was a subsequent 
influx of eosinophils [83], whereas this cell type 
was not prominent in either anaphylatoxin-
induced or delayed type reactions. Inasmuch as 
eosinophils are inhibited with respect to their 
directed and random migration by the neutrophil 
inhibitory factor (NIF) derived either from neutro-
phils or monocytes [88], it is possible to speculate 
that their absence in these latter lesions relates to 
the simultaneous presence of NIF. Also, the ratio of 
the mast cell-derived mediators may well be 
influenced by the nature of the activating process. 
Finally, although the mast cell can degranulate in 
immediate, subacute, and delayed type hypersen-
sitivity reactions in the human, the cell can also 
exhibit degranulation in response to nonimmuno-
logic stirn uli, such as codeine [89], curare [90], and 
possibly certain iodinated contrast materials [91], 
and to anaphylatoxins elaborated by the alterna-
tive complement pathway in response to its activa-
tion by complex microbial polysaccharides. 
The implication of the mast cell alterations in 
disease processes has been based almost entirely on 
morphologic criteria showing a change in the 
number of mast cells per mm 3 [65], or by structural 
alterations observed in toluidine blue-stained and 
routinely processed specimens [92], in I-p.m-thick 
sections [87], and in electron micrographs [85]. 
The availability of a sensitive radioenzyme assay 
for histamine [93], as well as techniques for the 
assessment of ECF -A in complex biologic fluids 
94], now makes it possible to use the concentra-
tions of these preformed mediators to confirm inde-
pendently whether or not the tissue mast cell con-
centration is altered. Activation of mast cells can 
be presumed not only by alterations of the cell by 
morphologic criteria or chemical mediator analysis , 
but also by the release of histamine [95-98] or 
ECF -A [94] into the circulation. It may even be 
possible to utilize the formation of unstored media-
tors such as SRS-A within the tissue as an alterna-
tive criterion for mast cell activation. 
It may be useful to consider the extent to which 
these parameters of mast cell activation (Table II) 
have been used to assess mast cell participation in 
disease processes with different mechanisms. In ex-
perimentally induced angioedema with urticaria in 
patients with clinical cold-induced urticaria, the 
venous blood of the affected extremity contains 
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TABLE II. Criteria for evaluation of the mast cell in 
disease processes 
Morphology 
Quantitative mast cell counts 
Qualitative mast cell alterations 
Nature of venular changes and cellular infiltrate 
Chemical Mediators 
Levels of preformed mediators in tissue 
Presence of preformed mediators in venous effluent 
Detection of newly generated mediators in lesional tis-
sue and/or venous effluent 
both histamine [95-98] and ECF -A [94] within 2 to 
5 min of challenge and for the subsequent 30-min 
period; there is no elevation of these mediators in 
the contralateral unchallenged extremity. The 
morphologic eVIdence of mast cell degranulation in 
routinely processed specimens [92] of experimental 
lesions together with the release of both preformed 
mast ,cell chemical mediators strongly implicates 
this cell type in the disease process. Neither 
quantitative morphologic studies nor analysis for 
chemical mediators in tissues are available in this 
disease. 
Mast cell hypogranulation is appreciated by the 
l-,um-thick section technique in the lesional site of 
patients with cutaneous necrotizing angiitis, both 
with and without hypocomplementemia [99]. In 
the hypocomplementemic form associated with the 
activation of the classic complement system in the 
case ofIgG-IgM cryoproteins and of the alternative 
pathway in the instance of IgG-IgA cryoprotein, it 
seems logical to invoke the action of anaphylatox-
ins on the tissue mast cells. In the normocom-
plementemic type, the predominance of lympho-
cytes over neutrophils, as well as the presence of 
activated lymphocytes, raises the question of 
delayed type hypersensitivity. Although the lym-
phocyte has been shown to release a migration 
inhibitory factor that prevents the random move-
ment of mouse mastocytoma cells on a glass 
surface [100] and an additional factor that causes 
the directed migration of human leukemic baso-
phils [101,102], a mast cell degranulating mecha-
nism has not been reported. In view of the subacute 
and chronic nature of these processes, it is unlikely 
that mast cell-derived mediators will be elevated 
in plasma or that newly generated mediators will 
be present in significant amounts in lesional tissue. 
Thus, further analysis of the contribution of the 
mast cell to the inflammatory process may well 
depend upon the use of agents that specifically 
inhibit generation and release of its mediators. 
Mastocytosis is a systemic disease that may 
involve many tissues, including the skin. When it 
is limited to the skin, it is termed urticaria 
pigmentosa [103]. The cutaneous lesions present as 
pigmented papules that become wheals after 
trauma. Quantitative mast cell counts in 4 
patients [65] showed a range of 262,400 to 384,000 
mast cells/mm 3 as compared to a mean of 7225 
cells/mm3 for normal subjects, and the, histamine 
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content has been noted to be increased in the 
lesional skin [104]. Degranulation following experi-
mentally induced trauma has been observed by 
ultrastructural studies [72-75], and patients with 
mastocytosis exhibit increased urinary histamine 
[105]. Using the skin window technique to study 
the appearance of cells into a lesional site of 
mastocytosis after scraping, eosinophils were 
prominent at 3 hr accompanied by neutrophils 
[106]. Whereas the response of patients with der-
mographism to trauma has been attributed to 
IgE-dependent mechanisms [107], the reaction in 
mastocytosis may merely reflect the number of 
mast cells available in the traumatized site. 
SUMMARY 
The mast cell in tissues represents an effector 
cell capable of elaboration of all the essential medi-
ators of inflammation. The effects of uncontrolled 
activation may be divided into pharmacologic and 
inflammatory phases with attendant implications 
for the ,initiation of both acute and subacute patho-
logic processes. The elaboration of chemical media-
tors by the mast cell makes it possible to recruit 
blood cells and proteins essential to host defense by 
a controlled physiologic process that can proceed 
without significant local tissue damage. When 
uncontrolled, the same potentiality can be injuri-
ous, with the nature of the clinical problem de-
pending upon the location of the cells, the intensity 
of activation, and the ratio of newly generated and 
preformed mediators released. The evidence that 
the mast cell can participate in each form of 
immunologic reaction-immediate, immune com-
plex, and delayed-as a primary or secondary 
effector cell and the diversity of its products 
foretell an evolving recognition of its role in host 
defense and tissue injury. It is pertinent to develop 
further methods and criteria to define the nature 
and extent of mast cell participation in disease 
processes. 
REFERENCES 
1. Schild HO, Hawkins DF, Mongar JL, Herxheimer 
H: Lancet 2:376, 1951 
2. Brocklehurst WE: J Physiol 151:416, 1960 
3. Kay AB, Austen KF: J Immunol 107:899, 1971 
4. Orange RP, Austen WG, Austen KF: J Exp Med 
134: 136s, 1971 
5. Bogart DB, Stechschulte DJ: Clin Res 22:652A, 1974 
6. Greaves MW, Yamamoto S, Fairley VM: Immunol-
ogy 23:239, 1972 
7. Jones DG, Kay AB: Clin Exp Immunol16:213, 1974 
8. Goetzl EJ, Ruddy S, Stechschulte DJ, Austen KF: 
In Pharmacology and Pharmacokinetics. Edited 
by T Teorell, RL Dedrick, PG Condliffe. New 
York, Plenum, 1974, p 281 
9. Crissey JT, Fergason JL, Bettenhausen JM: J 
Invest Dermatol 45:329, 1965 
10. Yamamoto S, Greaves MW, Fairley VM: Immunol-
ogy 24:77, 1973 
11. Ishizaka T, Ishizaka K, Orange RP, Austen KF: J 
Immunol 106:1267, 1971 
12. Cox JSG: Nature (Lond) 216:1328, 1967 
13. Sheard P, Blair AMJN: Int Arch Allergy Appl 
Immunol 38:217, 1970 
14. Assem ESK., Mongar JL: Int Arch Allergy Appl 
Immunol 38:68, 1970 
318 SOTER AND AUSTEN 
15. Gillespie E, Lichtenstein LM: J Clin Invest 51:2941 , 
1972 
16. Pearce CA, Greaves MW, Plummer VM, Yamamoto 
S: Clin Exp ImmunoI17:437, 1974 
17. Orange RP, Austen KF: In Progress in Immunology. 
Edited by B Amos. New York, Academic, 1971, p 
173 
18. Evans DP, Marshall PW, Thomson DS: Int Arch 
Allerg Appl Immunol 49:417, 1975 
19. Yamamoto S, Greaves MW, Fairley VM : Immunol-
ogy 24: 1007, 1973 
20. Orange RP: J Immunol 114:182, 1975 
21. Schayer RW: Fed Proc 24:1295, 1965 
22. Black JW, Duncan WAM, Durant CJ, Ganellin CR, 
Parsons EM: Nature (Lond) 236:385, 1972 
23. McNeill JH, Verma SC: J Pharmacol Exp Ther 
188:180, 1974 
24 . Dousa TP, Code CF: J Clin Invest 53:334, 1974 
25. Plaut M, Lichtenstein LM, Henney CS: J Clin 
Invest 55:856, 1975 
26. Lichtenstein LM, Gillespie E : J Pharmacol Exp 
Ther 192:441, 1975 
27 . Majno G, Palade GE, Schoefl GI: J Biophys Bio-
chem Cytol 11:607, 1961 
28. Nadel JA: Asthma: In Physiology, Immunophar-
macology and Tieatment . Edited by KF Austen , 
L Lichtenstein . New York, Academic , 1973, p 29 
29. Drazen JM, Austen KF: J Appl PhysioI38:834, 1975 
30. Kay AB, Stechschulte DJ, Austen KF: J Exp Med 
133:602, 1971 
31. Wasserman SI, Goetzl EJ , Austen KF: J Immunol 
290:420, 1974 
32. Lewis RA, Goetzl EJ, Wasserman SI, Valone FH, 
Rubin RH, Austen KF: J Immunol 114:87, 1975 
33. Goetzl EJ, Wasserman SI, Austen KF: In Progress 
in Immunology II, vol 4. Edited by L Brent, J 
Holborow. Amsterdam, North-Holland, 1974, p 
41 
34. Goetzl EJ, Austen KF: Proc Natl Acad Sci USA 
72:4123, 1975 
35. Wasserman SI, Whitmer D . Goetzl EJ , Austen KF: 
Proc Soc Exp BioI Med 148:301, 1975 
36. Wasserman SI, Goetzl EJ, Austen KF: J Immunol 
114:645, 1975 
37. Butterworth AE, Sturrock RF, Houba V, Mahmoud 
AAF, Sher A, Rees PH: Nature (Lond) 256:727, 
1975 
38. Orange RP, Murphy RC , Austen KF: J Immunol 
113:316, 1974 
39. Orange RP, Murphy RC, Karnovsky ML, Austen 
KF: J Immunol 110:760, 1973 
40. Wasserman SI, Austen KF: J Clin Invest 57:738, 
1976 
41. Lewis RA, Wasserman SI, Goetzl EJ , Austen KF: J 
Exp Med 140: 1133, 1974 
42. Orange RP: In Progress in Immunology II , vol 4. 
Edited by L Brent, J Holborow. Amsterdam, 
North-Holland, 1974, p 29 
43. Kaliner M, Wasserman SI, Austen KF: New Engl J 
Med 289:277, 1973 
44. Grant JA, Lichtenstein LM : J Immunol 112:897, 
1974 
45. Orange RP, Stechschulte DJ , Austen KF: J 
Immunol 105:1087, 1970 
46. Morse HC III, Bloch KJ , Austen KF: J Immunol 
101:658, 1968 
47. Orange RP , Austen KF: Adv Immunoll0:105, 1969 
48. Henson PM: J Exp Med 131:287, 1970 
49. Siraganian RP, Osler AG: J Immunol106: 1252, 1971 
50. Benveniste J: Nature (Lond) 249:581, 1974 
51. Kater LA, Goetzl EJ, Austen KF: J Clin Invest 
57:1173, 1976 
52. Webster ME, Horakova Z, Beaven' MA, Takahaski 
H, Newball HH: Fed Proc 33:761, 1974 
53 . Newball HH, Lichtenstein LM, Talamo RC: J 
Allergy 55:72, 1975 
54. Wasserman SI, Soter NA, Center DM, Austen KF: 
Clin Res 24:268a, 1976 
Vol. 67, No.3 
55. Kay AB, Shin H, Austen KF: Immunology 24:969, 
1973 
56. Weeks JR: Ann Rev Pharmacol 12:317, 1972 
57. Kaplan AP, Austen KF: J Allergy Clin Immunol 
56:491, 1975 
58. Cochrane CG, Revak SD, Aikin BS, Wuepper KD: 
In Inflammation: Mechanisms and Controls. 
Edited by IH Lepow, PA Ward. New York, 
Academic, 1972, p 119 
59 . Dawson W, Tomlinson R: Br J Pharmacol 52:107P, 
1974 
60. Dawson W, Sweatman WJF: Int Arch Allerg Appl 
Immunol 49:213, 1975 
61. Tauber ' AI, Kaliner M, Stechschulte DJ, Austen 
KF: J Immunol 111:27, 1973 
62. Stoner J , Manganiello VC , Vaughn M: Proc Natl 
Acad Sci USA 70:3830, 1973 
63. Greaves MW, McDonald-Gibson W: Br Med J 
3:608, 1973 
64. Bloom G: In The Inflammatory Process. Second 
edition. Edited by BW Zweifach, L Grant, RT 
McCluskey . New York, Academic, 1974, p 545 
65. Mikhail GR, Miller-Milinska A: J Invest Dermatol 
43:249, 1964 
66. Lagunoff D: J Invest Dermatol 58:296, 1972 
67 . Combs JW:· J Cell Biol31:563, 1966 
68. Fernando NVP , Movat HZ: Exp Mol Pathol 2:45U, 
1963 
69 . Kobayasi T , Midtgard K , Asboe-Hansen G: J 
Ultrastruct Res 23: 153, 1968 
70. Asboe-Hansen G: In The Skin. Edited by E Helwig, 
KF Mostofi. Baltimore, Williams & Wilkins, 
1971, p 83 
71. Trotter CM, Orr TSC: Clin Allergy 4:421, 1974 
72. Hashimoto K, Gross BG, Lever WF: J Invest 
Dermatol 46: 139, 1966 
73. Freeman RG: Am J Clin Pathol48: 187 , 1967 
74. Kobayasi T , Asboe-Hansen G: Acta Derm Venereol 
(Stockh) 49:369, 1969 
75. Moriyasu S, Yamura T : Acta Derm Venereol 
[Suppl] (Stockh) 73:149, 1973 
76. Lloyd AG, Bloom GD, Balazs EA: Biochem J 
103:76, 1967 
77. Lloyd AG, Bloom GD, Balazs EA, Haegermark 0: 
Biochem J 103:75, 1967 
78 . Yurt RW, Leid RW, Silbert JE, Spragg J, Austen 
KF: Fed Proc 35:865, 1976 
79. Lagunoff D, Benditt EP: Ann NY Acad Sci 103:185, 
1963 
80. Lagunoff D, Pritzl P, Mueller L: Exp Cell Res 
61:129, 1970 
81. Simpson JW, Taylor CA: Proc Soc Exp BioI Med 
145:42, 1974 
82. Prausnitz C, Kustner H: Zbl Bakt 86:160, 1921 
83 . Atkins P, Green GR, Zweiman B: J Allergy Clin 
Immunol 51 :263, 1973 
84. Vallota EH, M uller-Eberhard HJ: J Exp Med 
137:1109, 1973 
85. Lepow IH, Willms-Kretschmer K, Patrick RA, Ros-
en FS: Am J Pathol 61:13, 1970 
86 . Wuepper KD, Bokisch VA, Muller-Eberhard HJ, 
Stoughton RB: Clin Exp Immunol 11:13, 1972 
87. Dvorak H, Mihm MC Jr, Dvorak AM, Johnson RA, 
Manseau EJ, Morgan E , Colvin RB: Lab Invest 
31:111, 1974 
88. Goetzl EJ, Gigli I, Wasserman SI, Austen KF: J 
Clin Invest 111:938, 1973 
89. Schoenfeld MR: NY State J Med 60:2591, 1960 
90. Comroe JE Jr, Dripps RD: Anesthesiology 7:260, 
1946 
91. Obeid AI, Johnson L, Potts J, Mookherjee S, Eich 
R: Ann Intern Med 83:317, 1975 
92. Juhlin L, Shelley WB: JAMA 177:371, 1961 
93. Beaven MA, Jacobsen S, Horakova Z: Clin Chim 
Acta 37:91, 1972 
94. Soter NA, Wasserman SI, Austen KF: N Engl J 
Med 294:687, 1976 
95. Rose B: J Allergy 25:168, 1954 
Sept. 1976 
96. Henderson LL, Code CF, Roth GM: J Allergy 
29: 112, 1958 
97. Beall GN: J Allergy 34:8, 1963 
98. Kaplan AP, Gray L, Shaff RE, Horakova Z, Beaven 
MA: J Allergy Clin Immunol 55:394, 1975 
99. Soter NA: J Invest Dermatoi 67:354,1976 
100. Cohen MC, Zeschke R, Bigazzi PE, Yoshida Y, 
Cohen S: J Immunol 114:1641, 1975 
101. Kay AB, Austen KF: Clin Exp Immunol 11:557 , 
1972 
102. Ward PA, Dvorak HF, Cohen S, Yoshida R, Data R, 
Selvaggio S: J Immunol 114:1523, 1975 
103. Parker F, Odland GF: In Dermatology In General 
Medicine. Edited by TB Fitzpatrick, KA Arndt, 
WH Clark Jr, AZ Eisen, EJ VanScott , JH 
Vaughn. New York, McGraw-Hill, 1971, p 577 
104. Asboe-Hansen G: Acta Derm Venereol [Suppl] 
(Stockh) 73: 139, 1973 
105. Lindell SE, Rorsman H, Westling H: Acta Derm 
Venereol (Stockh) 41:277, 1961 
106. Wulff HR, Zachariae H, Oehlenschlaeger K: J 
Invest Dermatol 44:381, 1965 
107 . Newcomb RW, Nelson H: Am J Med 54:174, 1973 
DISCUSSIO N 
Sams: Does antigen bridging of mast cells with the 
resultant stimulation ofthe membrane result in release of 
all mediators, or might there be specific receptors for 
release of specific mediators? 
Austen: There are no data yet on the effect of different 
activating factors on the nature and ratio of mast cell 
products. 
Zucker-Franklin: Do you have any direct evidence for 
the interiorization of SRS-A by the eosinophil? Since 
arylsulfatase is a granule enzyme, one would have to 
assume that some form of degranulation or interioriza-
tion must occur for SRS-A to be inactivated. 
Austen: We assume SRS-A is taken up by eosinophils 
because inactivation occurs with resting intact cells and 
is prevented by metabolic inhibitors which do not influ-
ence the function of isolated eosinophil arysulfatase B. 
Also , inactivation occurs without release of eosinophil 
arysulfatase B. 
Kirkpatrick: It is still unclear whether the ratio of 
cAMP to cGMP or the absolute amounts of the nucleo-
tides are critical in modulating cell metabolism. It seems 
to me that you have an excellent model for answering this 
question. Do you have any data from direct measure-
ments of cyclic nucleotides that may indicate an answer 
to this problem? 
Austen: There are convincing data with regard to the 
relationship of cAMP and mediator release, but detailed 
data on cGMP in homogeneous cell systems are absent. 
Thus, kinetic studies of ratios of cAMP/cGMP are also 
lacking. 
Braverman: Sometimes one finds marked neutrophil-
ic infiltration in and around vessels in urticaria . Is 
NCF-A responsible? Can urticaria with these tissue 
changes be correlated with any clinical features in such 
patients, thus allowing one to select out certain kinds of 
stimuli that would trigger off urticaria with this histolog-
ic change? 
Austen: NCF-A is a mast cell preformed mediator that 
requires further characterization before its role in disease 
can be assessed. Urticaria with necrotizing angiitis is 
frequently associated with recurrent arthralgias and an 
increased sedimentation rate. 
Krueger: Are the increased numbers of mast cells seen 
in chronic atopic eczema secondary to migration or 
proliferation? 
Austen: The mechanism of local mast cell accumula-
tion is unknown but may be mast cell-dependent in terms 
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of some as yet unidentified primary mediator. 
Claman: There are many ways to degranulate mast 
cells, and you have used mainly an immunologic method. 
If, however , you use "nonspecific" mast cell degranula-
tors such as 48/80 or codeine, do you get ECF-A release 
and eosinophil accumulation? Do you get the generation 
of SRS-A? 
Austen: 48/80 in the rat releases histamine and 
ECF -A; in the human it produces histologic alterations of 
skin compatible with release of these two mediators. 
48/80 does not cause generation of SRS-A. 
Cohen: Lesions populated by infiltrating eosinophils 
differ from those involving neutrophil participation: 
eosinophils maintain their morphologic integrity and do 
not undergo a self destructive lytic process; and the 
lesions are not characterized by tissue necrosis or puru-
lent material. Do your studies offer any leads to explain 
this phenomenon; could there possibly be differences in 
respective cellular mechanisms for effecting release or 
utilization of their proteolytic enzyme contents? 
The findings of mast cell hyperplasia in affected 
tissues and increased IgE production seem to be charac-
teristic of patients with atopic dermatitis and those 
infected by migratory parasitic helminths . Yet there is a 
distinctively characteristic difference; the skin of the 
patient with atopic dermatitis demonstrates blanching 
on stroking. Do you have any information on possible 
qualitative differences among mast cell populations, e.g., 
presence of IgE receptors, and/or potential or actual 
ability to discharge histamine in response to challenges 
by specific antigens + reaginic antibody reactions or 
chemical, traumatic or inflammatory stimuli for degran-
ulation? 
Austen: We have no really discriminatory data of 
relevance to your first point except that these cells do 
differ in their content of certain enzymes . The precise 
relationship of mast cells to atopic dermatitis is unclear 
and may be largely in terms of increased mast concentra-
tion and elaboration of pruritic factors. 
Turk: To what extent can one extrapolate data 
derived from the mast cell to the basophil and vice versa? 
How do these cells compare at both the pharmacologic 
and cytologic levels? 
Austen: Circulatory basophils appear to lack the 
a-adrenergic and cholinergic receptors present in lung 
mast cells and thus exhibit receptor-related biochemical 
differences from tissue mast cells . Mediator data per cell 
are lacking in comparative quantitative terms, but quali-
tatively the mediators are the same. 
Dvorak: Basophils and mast cells are very different 
cells anatomically and have a separate and distinct 
lineage. Basophils are circulating granulocytes derived 
from bone marrow precursors similar to those of neutro-
phils and eosinophils. Mast cells are permanent residents 
of the tissues and their origins are not yet firmly 
established. In view of the similarities in the chemistry of 
their cytoplasmic granules and membrane receptors for 
IgE and the inverse nature of their relative frequency in 
different species, it is likely that basophils and mast cells 
are supplementary cells with related or identical func-
tions. Circulating in the blood, basophils may be quickly 
mobilized to a site of immunologic injury. By contrast, 
new mast cells must arise by a slower process of replica-
tion and differentiation which requires a period of days or 
weeks. Colvin and I have shown in renal allograft 
rejection in man a sequential arrival of basophils (early) 
and increased mast cells (late), findings which support 
the notion that basophils and mast cells may function 
sequentially in the same immunologic reaction [Lancet 
1:212, 1974]. 
